r&d spend - quarterly to 31 mar '13, page-7

Vinn, my comment about the Prof and "partners", simply refers in a general sense to his acquiring the cell technology "commercial rights" with a number of his medical colleagues over a decade ago - I have also heard that others, for example, the Pratt family have been heavily involved as investors from early days.

Obviously, all pharma companies, including MSB have ongoing relationships with senior scientific experts to roll out new fields of possible corporate activity for their technology as MSB have announced they will do later this year.

Best wishes.